# Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Source: https://onco.cc/trials/nct06001658/  
OnCo record `nct06001658` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.

## Summary

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers is a phase 2 interventional study registered as NCT06001658 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 27 participants, started 2024-07-08 and due to reach its primary completion in 2028-06. Interventions recorded: Gemcitabine, Cisplatin, Pembrolizumab. Conditions listed: Billiary Track Cancer. Gallbladder cancer is named in the registry entry: "* Must have a newly diagnosed, biopsy-proven biliary tract cancer (BTC) including gallbladder, intrahepatic, extrahepatic, and hilar cholangiocarcinoma.". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06001658
- Phase: 2
- Setting: Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT06001658: https://clinicaltrials.gov/study/NCT06001658

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06001658.json